首页> 外文期刊>Probiotics and Antimicrobial Proteins >Lactocin 160, a Bacteriocin Produced by Vaginal Lactobacillus rhamnosus, Targets Cytoplasmic Membranes of the Vaginal Pathogen, Gardnerella vaginalis
【24h】

Lactocin 160, a Bacteriocin Produced by Vaginal Lactobacillus rhamnosus, Targets Cytoplasmic Membranes of the Vaginal Pathogen, Gardnerella vaginalis

机译:Lactocin 160,一种由鼠李糖乳杆菌产生的细菌素,靶向阴道病原体,阴道加德纳菌的细胞质膜

获取原文
获取原文并翻译 | 示例
           

摘要

Bacterial vaginosis (BV) is a commonly occurring vaginal infection that is associated with a variety of serious risks related to the reproductive health of women. Conventional antibiotic treatment for this condition is frequently ineffective because the antibiotics tend to inhibit healthy vaginal microflora along with the pathogens. Lactocin 160, a bacteriocin produced by healthy vaginal lactobacilli, is a promising alternative to antibiotics; this compound specifically inhibits the BV-associated vaginal pathogens such as Gardnerella vaginalis and Prevotella bivia without affecting the healthy microflora. This study investigates the molecular mechanism of action for lactocin 160 and reveals that this compound targets the cytoplasmic membrane of G. vaginalis, causing the efflux of ATP molecules and dissipation of the proton motive force.
机译:细菌性阴道病(BV)是一种常见的阴道感染,与妇女生殖健康相关的各种严重风险有关。对于这种情况的常规抗生素治疗通常是无效的,因为抗生素倾向于与病原体一起抑制健康的阴道微生物群。 Lactocin 160是由健康的阴道乳杆菌产生的一种细菌素,是抗生素的有前途的替代品。该化合物可特异性抑制BV相关的阴道病原体,例如阴道加德纳菌和普通百日咳杆菌,而不会影响健康的菌群。这项研究调查了乳酸菌素160的分子作用机理,并揭示了该化合物靶向阴道加德纳氏菌的细胞质膜,从而导致ATP分子外流和质子动力的耗散。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号